Associated Papers
Molecular insights for the tumor suppressor role of SPOP in prostate cancer.
Yan P et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2026
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.
Wang R et al.
Cancer Research Communications, 2025
Comprehensive genomic landscape of metastatic hormone-sensitive prostate cancer in the Chinese population.
Yang B et al.
World Journal of Surgical Oncology, 2025
Deep Sequencing Reveals Novel Mutations in Androgen Receptor-Related Genes in Prostate Cancer.
Pedroza-Torres A et al.
International Journal of Molecular Sciences, 2025
Cancer-associated SPOP mutations enlarge nuclear size and facilitate nuclear envelope rupture upon farnesyltransferase inhibitor treatment.
Wang Z et al.
The Journal of Clinical Investigation, 2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Arun AS et al.
The Pharmacogenomics Journal, 2025
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation.
Gopal P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
The evolving landscape of prostate cancer somatic mutations.
Cotter K et al.
The Prostate, 2022
2-kupl: mapping-free variant detection from DNA-seq data of matched samples.
Wang Y et al.
Bmc Bioinformatics, 2021
Extreme value theory as a framework for understanding mutation frequency distribution in cancer genomes.
Tokutomi N et al.
Plos One, 2021
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.
Rao AA et al.
Frontiers in Immunology, 2020
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y et al.
Embo Molecular Medicine, 2019
Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P et al.
European Urology Oncology, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.
Spans L et al.
Oncotarget, 2016
Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P et al.
Human Mutation, 2014
SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M et al.
Neoplasia (new York, N.y.), 2014